StockData
Valneva SE logo

Valneva SE (VALN) stock

VALNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 17, 2026Score 1/30
$5.34−0.23 (-4.04%)

Close on Nov 18, 2026Market cap $463.35MP/E –Yield –

Valneva operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Valneva's operating income for the twelve months ending Jun 30, 2026 was -€115.11M. For fiscal 2025 it was -€82.06M, down 715.6% from the year before. The highest annual figure on record is €13.33M in fiscal 2024.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-€82.06M-715.6%
FY2024Dec 31, 2024€13.33M–
FY2023Dec 31, 2023-€82.09M–
FY2022Dec 31, 2022-€113.44M–
FY2021Dec 31, 2021-€61.39M–
FY2020Dec 31, 2020-€55.12M–
FY2019Dec 31, 2019-€811.00K–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-€26.19M–
Q1 FY2026Mar 31, 2026-€23.70M–
Q4 FY2025Dec 31, 2025-€28.12M–
Q3 FY2025Sep 30, 2025-€37.12M–
Q2 FY2025Jun 30, 2025-€10.87M–
Q1 FY2025Mar 31, 2025-€5.96M-108.7%
Q4 FY2024Dec 31, 2024-€20.88M–
Q3 FY2024Sep 30, 2024-€12.45M–
Q2 FY2024Jun 30, 2024-€21.55M–
Q1 FY2024Mar 31, 2024€68.21M–
Q4 FY2023Dec 31, 2023-€24.91M–
Q3 FY2023Sep 30, 2023-€22.21M-123.8%
Q2 FY2023Jun 30, 2023-€18.39M–
Q1 FY2023Mar 31, 2023-€16.57M–
Q4 FY2022Dec 31, 2022-€56.35M-132.0%
Q3 FY2022Sep 30, 2022€93.32M–
Q2 FY2022Jun 30, 2022-€131.99M–
Q1 FY2022Mar 31, 2022-€18.42M–
Q4 FY2021Dec 31, 2021€176.21M–
Q3 FY2021Sep 30, 2021-€151.43M–
Q2 FY2021Jun 30, 2021-€55.03M–
Q1 FY2021Mar 31, 2021-€31.14M–

More Valneva figures

See a number that looks wrong?